Abstract
Purpose: To improve the local control of stage III non-small cell lung cancer, we tried concurrent chemoradiotherapy with daily low-dose cisplatin during the first 5 weeks of conventional radiotherapy. Material and Methods: Ten consecutive patients with stage III non-small cell lung cancer were treated with chemoradiotherapy with 66 Gy in conventional fractionation and concurrent daily low-dose cisplatin (4mg/m2), which was given 5 days per week (from Monday to Friday) for the first 5 weeks. Results: There was no case with>grade 3 toxicity. The median survival was 14.6 months, and the 2-year local progression-free survival rate was 35%. Conclusion: Daily low-dose cisplatin combined with conventional radiotherapy was considered to be feasible and to have the possibility to offer better local control than radiotherapy alone in the treatment of stage III non-small cell lung cancer.
